Sturge-Weber Syndrome (SWS)

1. Clinical Overview

Summary

Sturge-Weber Syndrome (SWS) is a rare, non-hereditary neurocutaneous disorder characterized by the clinical triad of:

1. Facial port-wine stain (PWS) - capillary malformation in trigeminal nerve distribution
2. Leptomeningeal angiomatosis - ipsilateral pial vascular malformation
3. Ocular abnormalities - glaucoma and choroidal haemangioma

Unlike other phakomatoses (neurofibromatosis, tuberous sclerosis), SWS is caused by a somatic mosaic mutation in the GNAQ gene occurring post-fertilization. This results in sporadic occurrence with virtually no recurrence risk in siblings. The condition affects approximately 1 in 20,000-50,000 live births with equal gender distribution. [1,2]

The hallmark dermatological feature is a port-wine stain (capillary malformation) in the distribution of the ophthalmic (V1) and/or maxillary (V2) divisions of the trigeminal nerve. When the PWS involves the V1 distribution (forehead and upper eyelid), there is approximately 25% risk of underlying leptomeningeal angiomatosis. [3]

The neurological manifestations dominate clinical outcomes and include:

• Epilepsy (75-90% of patients) - often refractory, typically focal motor seizures
• Hemiparesis - contralateral to the vascular malformation
• Intellectual disability - severity correlates with seizure control
• Stroke-like episodes - episodic neurological deficits
• Headaches - migraine-like episodes

Early diagnosis and aggressive multidisciplinary management are essential to optimize neurodevelopmental outcomes. [4,5]

Key Facts

• Genetics: Post-zygotic somatic mutation in GNAQ gene (chromosome 9q21)

  • "Mutation: c.548G>A (p.Arg183Gln) in ~88% of cases"
  • Activating mutation in G-protein signaling pathway
  • Sporadic - NOT inherited
  • Present in affected tissue only (mosaic distribution) [6,7]

• The Classic Triad:

  1. Cutaneous: Unilateral facial port-wine stain (V1 ± V2/V3 distribution)
  2. Neurological: Ipsilateral leptomeningeal angiomatosis (occipital > parietal > temporal > frontal)
  3. Ophthalmological: Glaucoma (30-70%), choroidal haemangioma, retinal vascular tortuosity

• Classification (Roach Scale):

  • "Type I: Both facial PWS and leptomeningeal angiomatosis ± glaucoma"
  • "Type II: Facial PWS alone ± glaucoma (no brain involvement)"
  • "Type III: Isolated leptomeningeal angiomatosis ± glaucoma (no facial PWS) - rare [8]"

• Radiological Hallmarks:

  • ""Tram-track" calcification: Gyriform cortical calcification on CT"
  • "Leptomeningeal enhancement: Pial angiomatosis on contrast MRI"
  • "Cortical atrophy: Progressive hemiatrophy"
  • "Enlarged ipsilateral choroid plexus: Venous congestion marker [9,10]"

Clinical Pearls

"V1 Determines Brain Risk": Only port-wine stains involving the ophthalmic (V1) dermatome (forehead, upper eyelid) carry significant risk (~25%) of underlying leptomeningeal angiomatosis. Isolated V2/V3 involvement has minimal brain risk. [3]

"The Eye Emergency": Every infant with V1 port-wine stain requires urgent ophthalmology assessment within first weeks of life. Congenital glaucoma (buphthalmos) can cause irreversible vision loss if untreated. [11]

"Cortical Not Vascular Calcium": The pathognomonic "tram-track" calcification is in the ischaemic cortex underlying the angioma, not in the blood vessels themselves. It represents dystrophic calcification of chronically hypoxic neurons. [9]

"Earlier Seizures = Worse Outcome": Seizure onset before 12 months of age is the strongest predictor of poor neurodevelopmental outcome. Early aggressive seizure control is paramount. [12]

"Hemispherectomy is Curative": For drug-resistant epilepsy with established hemiplegia, functional hemispherectomy achieves seizure freedom in > 80% and often improves cognitive function despite removing/disconnecting half the brain. [13]

---

2. Epidemiology

Incidence and Prevalence

Demographic Distribution

• Age of presentation:
  • "Port-wine stain: Present at birth"
  • "Seizures: 75% onset in first year of life"
  • "Glaucoma: Can be congenital or develop through childhood/adulthood"
• Ethnicity: No known ethnic predilection
• Geographic distribution: Worldwide occurrence [1,2]

Port-Wine Stain Risk Stratification

Exam Detail: Examination Relevance: In MRCPCH clinical examinations, recognizing the V1 distribution pattern is critical. Examiners commonly present images of facial port-wine stains asking candidates to identify high-risk features requiring neuroimaging and ophthalmology referral.

---

3. Aetiology and Pathophysiology

Molecular Genetics

The GNAQ Mutation

Gene: GNAQ (guanine nucleotide-binding protein G(q) subunit alpha)

• Location: Chromosome 9q21
• Function: Encodes Gαq protein subunit of heterotrimeric G-proteins
• Role: Regulates intracellular signal transduction via phospholipase C-β (PLC-β) pathway

Mutation Details:

• Type: Missense mutation - c.548G>A
• Protein change: p.Arg183Gln (R183Q)
• Frequency: Found in ~88% of SWS tissue samples
• Mechanism: Constitutive activation of Gαq signaling
• Timing: Post-zygotic (somatic) mutation during early embryogenesis [6,7]

Why Somatic Mosaicism?

The mutation occurs in a progenitor cell after fertilization but before neural crest and ectodermal lineage separation. This explains:

1. Non-inheritance: Mutation not present in germline (eggs/sperm)
2. Tissue-specific distribution: Only affects derivatives of mutated progenitor cell
3. Unilateral involvement: Mutation in one hemispheric precursor
4. Variable phenotype: Depends on timing and location of mutation [6]

Exam Detail: Molecular Mechanism: The R183Q mutation prevents GTPase activity of Gαq, locking it in the active GTP-bound state. This causes:

• Constitutive activation of PLC-β
• Increased IP₃ and DAG production
• Dysregulated calcium signaling
• Abnormal endothelial cell proliferation
• Impaired vascular maturation

This mechanism has therapeutic implications - MEK inhibitors and other pathway-targeted therapies are under investigation. [14]

Embryological Basis

Critical Developmental Window: Weeks 4-8 of gestation

The trigeminal nerve territory and overlying skin share common embryonic origin:

• Ectoderm: Forms facial skin
• Neural crest: Contributes to meningeal vasculature
• Neuroectoderm: Forms cerebral cortex

A GNAQ mutation in their common precursor explains the anatomical correlation between:

• V1 skin territory → Port-wine stain
• Ipsilateral leptomeninges → Angiomatosis
• Uveal tract → Choroidal haemangioma [3]

Vascular Pathophysiology

The Leptomeningeal Angiomatosis

Structure:

• Abnormal proliferation of thin-walled venous capillaries in the pia mater
• Most commonly involves occipital and posterior parietal regions
• Can be unilateral or bilateral (Type 3)

Haemodynamic Consequences:

1. Venous stasis: Malformed vessels have poor drainage
2. Chronic hypoxia: Underlying cortex receives inadequate perfusion
3. "Steal phenomenon": Angioma diverts blood from normal parenchyma
4. Elevated venous pressure: Impairs arterial perfusion [15]

The Cascade of Cortical Injury

Leptomeningeal Angiomatosis
          ↓
   Venous Stasis + Congestion
          ↓
   Chronic Cortical Hypoxia
          ↓
   ┌──────────┴──────────┐
   ↓                     ↓
Neuronal Injury    Seizure Focus
   ↓                     ↓
Gliosis + Calcification  Epilepsy
   ↓                     ↓
 Atrophy           Neurodevelopmental
   ↓                   Impairment
Hemiatrophy              ↓
   ↓                 Hemiparesis
Progressive Deficit   Intellectual Disability

Cortical Calcification ("Tram-Track" Sign)

• Location: Gyral cortex (layers II-III) underlying angioma
• Pathology: Dystrophic calcification of dead/dying neurons
• Timing: Usually visible on CT after 2 years of age
• Progression: Increases with age
• Clinical correlation: Extent correlates with seizure severity [9,10]

Ocular Pathophysiology

Glaucoma Mechanism

Primary mechanism: Elevated episcleral venous pressure

1. Choroidal haemangioma → venous congestion
2. Increased pressure in episcleral veins
3. Impaired aqueous humour drainage via trabecular meshwork
4. Elevated intraocular pressure (IOP)
5. Optic nerve damage → visual field loss → blindness [11]

Types in SWS:

• Congenital glaucoma: Presents at birth with buphthalmos (enlarged globe)
• Infantile glaucoma: Develops in first 3 years
• Late-onset glaucoma: Can occur in adolescence/adulthood

---

4. Clinical Presentation

Dermatological Features

Port-Wine Stain (Naevus Flammeus)

Characteristics:

• Appearance at birth: Flat, pink-to-red macule
• Evolution: Darkens to purple/deep red with age
• Texture changes: Can develop nodules, blebs, or "cobblestoning" in adulthood
• Distribution:
  • Usually unilateral
  • V1 (ophthalmic) ± V2 (maxillary) ± V3 (mandibular)
  • Sharp midline demarcation
  • Does NOT cross midline (with rare exceptions)

Clinical Significance by Location:

• V1 involvement: 25% risk of leptomeningeal angiomatosis → requires MRI brain
• V1 + V2/V3: ~50% risk of brain involvement
• Bilateral PWS: Consider Type 3 SWS or other diagnoses [3]

Natural History:

• Persists throughout life (does NOT fade spontaneously)
• Progressive darkening and thickening
• Cosmetic and psychological impact significant [16]

Neurological Features

Epilepsy (75-90% of patients)

Onset:

• 75% begin in first year of life
• Median age: 6 months
• Earlier onset correlates with worse cognitive outcome [12]

Seizure Types:

• Focal motor seizures: Most common
  • Contralateral to angioma
  • Can progress to bilateral tonic-clonic
  • Todd's paralysis common (post-ictal hemiparesis)
• Epileptic spasms: Can mimic West syndrome in infancy
• Status epilepticus: Higher risk than general epilepsy population

EEG Findings:

• Voltage asymmetry: Reduced amplitude over affected hemisphere (due to calcification/atrophy)
• Focal slowing: Ipsilateral to angioma
• Epileptiform discharges: Focal spikes, sharp waves
• Background asymmetry: Prognostic marker [17]

Hemiparesis

Characteristics:

• Contralateral to leptomeningeal angiomatosis
• Progressive: Insidious worsening due to cortical atrophy
• Stepwise: Abrupt worsening with stroke-like episodes or status epilepticus
• Spasticity: Upper motor neuron pattern
• Variable severity: Mild weakness to complete hemiplegia

Timing:

• Can be present from birth
• Often becomes apparent when seizures begin
• Progressive deterioration without intervention [15]

Intellectual Disability

Prevalence: 50-60% of SWS patients Severity: Highly variable (borderline to profound)

Predictive Factors:

• Earlier seizure onset (less than 12 months): Worse outcome
• Bilateral brain involvement: Severe impairment
• Poor seizure control: Progressive cognitive decline
• Extent of cortical involvement: Larger angioma = worse prognosis [12]

Stroke-Like Episodes

Presentation:

• Acute onset focal neurological deficits
• Hemiparesis, hemisensory loss, aphasia, visual field defects
• Duration: Hours to days
• Can be recurrent

Pathophysiology (debated):

• Vascular steal: Seizure increases metabolic demand → relative ischaemia
• Prolonged post-ictal (Todd's) paralysis: Enhanced by underlying vascular insufficiency
• Venous thrombosis: Sluggish flow in angioma
• NOT typically true arterial stroke [18]

Significance: Often triggers neuroimaging and diagnosis in previously unrecognized SWS

Headaches

• Migraine-like: With or without aura
• Mechanism: Vascular dysregulation, cortical spreading depression
• Frequency: Common, often refractory to standard migraine therapy

Ophthalmological Features

Glaucoma (30-70% of patients)

Congenital/Infantile Glaucoma (buphthalmos):

• Signs:
  • Enlarged corneal diameter (> 11mm in newborn, > 12mm at 1 year)
  • Corneal clouding (oedema)
  • Epiphora (excessive tearing)
  • Photophobia
  • Horizontal corneal striae (Haab's striae)
• Diagnosis: Requires examination under anaesthesia (EUA) in infants
• IOP measurement: Tonometry [11]

Late-Onset Glaucoma:

• Insidious onset
• Often asymptomatic until advanced
• Regular IOP screening essential throughout life

Choroidal Haemangioma

• "Tomato ketchup fundus": Diffuse reddish discoloration
• Location: Usually posterior pole
• Complications: Exudative retinal detachment, secondary glaucoma
• Imaging: Enhanced depth imaging OCT, ultrasound [11]

Other Ocular Features

• Heterochromia iridis (iris colour asymmetry)
• Tortuous retinal vessels
• Hemianopsia (from occipital lobe involvement)

Systemic Features

Generally absent: SWS is primarily neurocutaneous Exceptions:

• Oral/gingival vascular malformations (if V2/V3 involved)
• Occasional limb vascular malformations (rare, consider alternative diagnoses)

---

5. Differential Diagnosis

Key Differentials

Clinical Pearl: Bilateral Involvement: If bilateral facial PWS or bilateral leptomeningeal angiomatosis, consider:

1. Type 3 SWS (bilateral brain involvement, no PWS)
2. Coincidental bilateral PWS (rare)
3. Alternative vascular syndrome
4. Genetic testing may identify rare syndromic associations

---

6. Investigations

Neuroimaging

MRI Brain with IV Gadolinium Contrast (Gold Standard)

Indications: All patients with V1 port-wine stain, regardless of symptoms

Optimal Timing:

• Neonatal period (birth-3 months): Leptomeningeal enhancement visible
• After 6-12 months: Cortical changes become apparent
• Serial imaging: Monitor progression [9,10]

Key Findings:

Prognostic Imaging Markers:

• Extent of leptomeningeal involvement
• Degree of atrophy at presentation
• Bilateral involvement (worse prognosis) [10]

CT Head (Non-Contrast)

Primary Role: Detection of cortical calcification

Findings:

• "Tram-track" calcification: Gyriform, parallel lines following cortical gyri
• Location: Underlying leptomeningeal angiomatosis (occipital/parietal most common)
• Timing: Usually not visible before 2 years of age; increases with age
• Sensitivity: Superior to MRI for calcification detection [9]

Indications:

• Complement to MRI (not replacement)
• Assessment of calcification extent
• Emergency setting (seizures, stroke-like episode)

Advanced Imaging Modalities

Perfusion MRI/CT:

• Demonstrates reduced cerebral blood flow in affected regions
• Useful for surgical planning

MR Spectroscopy:

• Reduced NAA (neuronal marker) in affected cortex
• Elevated lactate (metabolic stress)

PET Scan (rare, research settings):

• Hypometabolism in affected hemisphere
• Predicts epilepsy surgery outcomes

Electroencephalography (EEG)

Standard EEG:

• Voltage depression: Reduced amplitude over affected hemisphere (atrophy/calcification)
• Focal slowing: Ipsilateral to angioma
• Epileptiform activity: Focal spikes, sharp waves
• Background asymmetry: Predictor of epilepsy severity [17]

Video-EEG Monitoring:

• Seizure characterization
• Pre-surgical evaluation for epilepsy surgery
• Differentiate seizures from stroke-like episodes

Ophthalmological Assessment

Essential for ALL patients with V1 PWS

Investigations:

Examination Under Anaesthesia (EUA):

• Required in infants/young children for accurate IOP measurement
• Assess corneal diameter, clarity
• Comprehensive fundoscopy [11]

Genetic Testing

Clinical Genetic Testing:

• Tissue required: Skin biopsy from port-wine stain (NOT blood)
• Technique: Next-generation sequencing for GNAQ c.548G>A mutation
• Sensitivity: ~88% (not all SWS have detectable mutation)
• Clinical utility: Confirmatory, but diagnosis is clinical [6,7]

Indications:

• Atypical presentations
• Genetic counselling (confirm somatic, not germline)
• Research purposes

Limitations:

• Mutation may be present at low levels (mosaicism) → false negatives
• Not necessary for diagnosis in typical cases

Developmental Assessment

Recommended for all patients:

• Neurodevelopmental screening: Ages and Stages Questionnaire, Denver II
• Formal psychometric testing: Age-appropriate (Bayley, WISC, WAIS)
• Speech and language assessment: If delays suspected
• Occupational therapy assessment: Motor skills, activities of daily living
• Educational psychology input: School-age children [12]

---

7. Management

Multidisciplinary Team Approach

Essential Team Members:

• Paediatric neurologist (lead coordinator)
• Epilepsy nurse specialist
• Paediatric ophthalmologist
• Dermatologist (laser therapy)
• Neurosurgeon (if epilepsy surgery candidate)
• Clinical geneticist
• Developmental paediatrician
• Physiotherapy, occupational therapy, speech and language therapy
• Educational psychology
• Clinical psychology (family support)

Management Algorithm

         Diagnosis: V1 PWS ± Neurological Symptoms
                         ↓
         ┌───────────────┼───────────────┐
         ↓               ↓               ↓
    MRI BRAIN      OPHTHALMOLOGY    BASELINE EEG
         ↓               ↓               
  Leptomeningeal    IOP, Fundoscopy     
   Angiomatosis?         ↓               
         ↓          Glaucoma?            
    ┌────┴────┐          ↓               
    ↓         ↓     ┌────┴────┐          
 Seizures?   No    Yes       No          
    ↓      Seizures ↓         ↓          
    ↓         ↓    TREAT   MONITOR       
 ANTI-    MONITOR GLAUCOMA  (3-6 monthly)
EPILEPTIC   (Annual ↓                    
  DRUGS    MRI)  Drops/Surgery           
    ↓                                    
Drug-Resistant                           
 Epilepsy?                               
    ↓                                    
   Yes                                   
    ↓                                    
EPILEPSY SURGERY EVALUATION              
    ↓                                    
Hemispherectomy/Hemispherotomy           
    ↓                                    
SEIZURE FREEDOM (80%+)                   

         +
         
    DERMATOLOGY
         ↓
  Pulsed Dye Laser
     (Lifelong)

Neurological Management

1. Antiepileptic Drug (AED) Therapy

First-Line AEDs (Focal Seizures):

Second-Line/Adjunctive AEDs:

• Topiramate (5-9 mg/kg/day)
• Valproate (20-40 mg/kg/day) - avoid in girls/women of childbearing age
• Clobazam (0.5-1 mg/kg/day)
• Lacosamide, perampanel (limited paediatric data)

Monitoring:

• Seizure frequency diary
• Developmental progress
• AED levels (where appropriate)
• Adverse effects screening [4,5]

2. Aspirin Therapy (Controversial)

Rationale:

• Prevent venous thrombosis in sluggish leptomeningeal vessels
• Reduce frequency/severity of stroke-like episodes
• Improve cortical perfusion [18]

Evidence:

• Limited RCT data
• Retrospective studies suggest benefit for stroke-like episodes
• Widely used in clinical practice despite weak evidence base

Dosing:

• Low-dose aspirin: 3-5 mg/kg/day (max 75-81 mg/day)
• Start after diagnosis, continue lifelong in many centers

Contraindications:

• Active bleeding
• Aspirin allergy
• Concurrent anticoagulation
• Severe liver disease

Monitoring:

• No routine platelet function testing required
• Counsel regarding Reye's syndrome risk (avoid during viral illness - controversial)

Evidence Debate: Aspirin in SWS: The evidence base for aspirin is weak but growing. A 2018 retrospective study showed reduced stroke-like episodes in aspirin-treated patients. Ongoing prospective studies may clarify optimal patient selection. Current practice varies widely between centers. [18]

3. Surgical Management of Epilepsy

Indications for Epilepsy Surgery:

• Drug-resistant epilepsy (failure of ≥2 appropriate AEDs)
• Established hemiparesis (patient has "nothing to lose" motorically)
• Progressive cognitive decline despite AED therapy
• Unilateral, well-defined leptomeningeal angiomatosis on imaging
• Early surgery considered for seizure onset less than 1 year with poor control [13]

Surgical Options:

a) Functional Hemispherectomy/Hemispherotomy (Procedure of Choice)

Principle: Disconnect affected hemisphere while leaving tissue in situ

Technique:

1. Complete corpus callosotomy
2. Disconnection of frontal and parietal lobes from brainstem
3. Temporal lobectomy (includes mesial structures)
4. Disconnection of occipital lobe
5. Result: Isolated, non-functioning hemisphere

Outcomes in SWS:

• Seizure freedom: 80-90% (Engel Class I)
• Cognitive outcomes: Often improved (seizure burden removed)
• Motor outcomes: Hemiplegia persists (usually already present)
• Visual outcomes: Homonymous hemianopia (expected)
• Quality of life: Significant improvement in most patients [13]

Complications:

• Hydrocephalus (10-20%) - may require shunt
• Bleeding
• Infection
• Aseptic meningitis
• Shift of midline structures (avoided by leaving tissue in place vs anatomical hemispherectomy)

b) Focal Resection/Lobectomy

• Indications: Very limited angiomatosis confined to one lobe
• Outcomes: Less effective than hemispherectomy if multifocal involvement
• Advantage: Potentially less motor/visual deficit

Pre-Surgical Evaluation:

• High-resolution MRI with contrast
• Video-EEG monitoring (identify seizure focus)
• Neuropsychological assessment
• Functional MRI (language lateralization)
• Wada test (if hemispherectomy considered - assess language/memory in remaining hemisphere)
• PET/SPECT (selected cases) [13]

Timing of Surgery:

• Early intervention (age 2-5 years) increasingly advocated for drug-resistant cases
• Neuroplasticity maximal in young children
• Prevents cumulative damage from ongoing seizures
• Preserves cognitive potential

Clinical Pearl: "The Hemispherectomy Paradox": Parents often struggle with the concept of removing/disconnecting half their child's brain. The key counselling point: the diseased hemisphere is actively damaging the healthy one through ongoing seizures. Removing the "bad" hemisphere protects the "good" one and unmasks its remarkable plasticity. Most children function far better post-operatively than predicted. [13]

Ophthalmological Management

Glaucoma Treatment

Medical Management (First-Line):

Surgical Management:

Indications:

• Uncontrolled IOP on maximal medical therapy
• Congenital glaucoma (buphthalmos) - often requires surgery
• Progressive visual field loss
• Optic nerve damage [11]

Surgical Options:

1. Goniotomy/Trabeculotomy (Infants):

   • First-line for congenital glaucoma
   • Success rate: 60-80% initially, but many require repeat procedures

2. Trabeculectomy with Mitomycin-C:

   • Creates new drainage pathway (bleb)
   • Higher success rate but more complications
   • Significant risk of late failure in SWS (episcleral venous pressure remains elevated)

3. Glaucoma Drainage Devices (Tubes):

   • Ahmed, Baerveldt, Molteno valves
   • Increasingly used as first-line surgical option in SWS
   • Better long-term IOP control than trabeculectomy
   • Success rate: 70-80% at 5 years

4. Cyclodestructive Procedures:

   • Diode laser cyclophotocoagulation
   • Reserved for refractory cases
   • Destroys ciliary body (↓ aqueous production)

Prognosis: Glaucoma in SWS is challenging to control. Many patients require multiple surgeries. Vision preservation depends on early detection and aggressive management. [11]

Choroidal Haemangioma Management

Observation: Small, asymptomatic lesions

Treatment (if symptomatic or exudative changes):

• Photodynamic therapy (PDT)
• Laser photocoagulation
• External beam radiotherapy (rarely used now)
• Anti-VEGF injections (emerging evidence)

Dermatological Management

Pulsed Dye Laser (PDL) Therapy

Mechanism: Selective photothermolysis

• Target chromophore: Oxyhaemoglobin
• Wavelength: 585-595 nm (yellow light)
• Pulse duration: 0.45-40 ms (matches thermal relaxation time of capillaries)
• Effect: Selective destruction of PWS capillaries without epidermal damage [16]

Treatment Protocol:

• Start early: Ideally in first year of life (thinner skin, smaller vessels, better response)
• Frequency: Every 6-12 weeks (allow healing between treatments)
• Sessions required: Highly variable (10-20+ treatments typical)
• Anaesthesia: General anaesthesia in infants/young children; topical/local in older children

Outcomes:

• > 75% lightening: ~50% of patients
• Complete clearance: Rare (less than 10%)
• Darker/thicker PWS: More resistant to treatment
• Facial location: V1 responds better than V2/V3
• Long-term maintenance: Often required to prevent re-darkening [16]

Side Effects:

• Purpura (expected, resolves in 7-14 days)
• Hyperpigmentation (temporary in most cases)
• Hypopigmentation (permanent risk, especially in darker skin)
• Scarring (rare with appropriate settings)
• Atrophic scarring (very rare)

Emerging Therapies:

• Longer wavelength lasers (1064 nm Nd:YAG) for deeper/darker PWS
• Topical sirolimus (mTOR inhibitor) - in clinical trials
• MEK inhibitors (targeting GNAQ pathway) - preclinical

Clinical Pearl: Realistic Expectations: Counsel families that complete clearance is unlikely, but significant lightening is achievable in most cases. The psychosocial benefit of even partial improvement is substantial, especially if started early in childhood. [16]

Neurodevelopmental Support

Early Intervention Services:

• Physiotherapy: Manage hemiparesis, prevent contractures, maximize mobility
• Occupational therapy: Fine motor skills, activities of daily living
• Speech and language therapy: Communication, feeding (if bulbar involvement)
• Educational support: Individualized education plan (IEP), special educational needs (SEN) provision

Monitoring:

• Regular developmental assessments
• School performance monitoring
• Transition planning (adolescence → adulthood)

Psychosocial Support

For Child:

• Psychological support for visible difference (PWS)
• Coping strategies for chronic illness
• Peer support groups

For Family:

• Genetic counselling (reassurance about recurrence risk)
• Information about prognosis
• Support groups (Sturge-Weber Foundation, UK SWS support groups)
• Respite care
• Sibling support

---

8. Prognosis and Outcomes

Overall Prognosis

Highly Variable - depends on:

1. Extent of leptomeningeal angiomatosis
2. Age of seizure onset
3. Response to antiepileptic therapy
4. Presence of bilateral involvement
5. Timing and success of interventions [12]

Neurological Outcomes

Predictors of Poor Neurodevelopmental Outcome [12]:

• Seizure onset before 12 months of age (strongest predictor)
• Bilateral brain involvement
• Extensive leptomeningeal angiomatosis
• Early cortical atrophy on MRI
• Poor seizure control
• Status epilepticus

Predictors of Better Outcome:

• Later seizure onset (or no seizures)
• Unilateral, limited involvement
• Good seizure control with AEDs
• Early hemispherectomy for drug-resistant cases

Ophthalmological Outcomes

Key: Regular lifelong ophthalmology follow-up essential [11]

Dermatological Outcomes

• PWS persists throughout life
• Darkens and thickens with age without treatment
• PDL therapy can achieve 50-75% lightening in many cases
• Complete clearance rare
• Psychosocial impact significant (body image, self-esteem) [16]

Mortality

• Not life-limiting in most cases
• Mortality risk primarily from:
  • Status epilepticus
  • Sudden unexpected death in epilepsy (SUDEP) - if poor seizure control
  • Complications of neurosurgery (rare)
• Life expectancy can be normal with good seizure control and supportive care

Quality of Life

Major Determinants:

1. Seizure control
2. Cognitive function
3. Visual function
4. Psychosocial adjustment to facial PWS
5. Family support systems

Improving Quality of Life:

• Early aggressive seizure management
• Consider early hemispherectomy for drug-resistant epilepsy
• Optimize glaucoma control
• Early PDL for PWS
• Comprehensive neurodevelopmental support
• Psychological support for child and family

---

9. Complications

Neurological Complications

Ophthalmological Complications

Surgical Complications

Hemispherectomy:

• Hydrocephalus (10-20%): May require VP shunt
• Bleeding: Intraoperative or post-operative
• Infection: Meningitis, cerebritis
• Aseptic meningitis
• Expected deficits: Hemiplegia (usually pre-existing), homonymous hemianopia

Glaucoma Surgery:

• Bleb failure (trabeculectomy)
• Hypotony
• Tube erosion/exposure (drainage devices)
• Endophthalmitis (rare but serious)

Psychosocial Complications

• Low self-esteem (visible PWS)
• Social isolation
• Depression/anxiety
• Educational underachievement
• Family stress
• Caregiver burden

---

10. Prevention and Screening

Primary Prevention

Not possible - somatic mutation is sporadic, occurs post-fertilization

• No lifestyle or environmental risk factors identified
• Not inherited - no role for pre-conception counselling
• Prenatal diagnosis not applicable (mutation not detectable in standard prenatal testing)

Secondary Prevention (Early Detection and Intervention)

At Birth:

• Identify all facial port-wine stains
• Determine trigeminal distribution (V1 is high-risk)

V1 PWS Identified → Immediate Referral Pathway:

    V1 Port-Wine Stain at Birth
              ↓
    ┌─────────┴─────────┐
    ↓                   ↓
OPHTHALMOLOGY      PAEDIATRIC NEUROLOGY
(within 4 weeks)     (within 3 months)
    ↓                   ↓
IOP measurement     MRI brain (contrast)
Fundoscopy          Baseline EEG
    ↓                   ↓
Glaucoma?           Leptomeningeal
    ↓               Angiomatosis?
  TREAT                 ↓
                    MONITOR for seizures
                    (Parents educated)

Screening Protocols:

Ophthalmology:

• Birth-2 years: IOP check every 3-6 months (more frequent if glaucoma risk)
• 2-18 years: Annual comprehensive eye exam
• Adults: Annual exam lifelong

Neurology:

• If leptomeningeal angiomatosis: Seizure monitoring; developmental surveillance
• Annual MRI in first few years to assess progression
• If seizures develop: Optimize AED therapy; consider early surgical evaluation if drug-resistant

Dermatology:

• Initiate PDL therapy in first year of life for best outcomes
• Counsel about natural history (darkening, thickening)

Tertiary Prevention (Preventing Complications)

Seizure-related:

• Early aggressive AED therapy
• Low threshold for epilepsy surgery evaluation if drug-resistant
• SUDEP prevention: Nocturnal supervision, optimize control

Glaucoma-related:

• Lifelong regular IOP monitoring
• Prompt treatment of elevated IOP
• Prevent vision loss through early intervention

Neurodevelopmental:

• Early intervention services
• Educational support
• Prevent secondary psychosocial morbidity

---

11. Key Guidelines and Evidence

Major Clinical Guidelines

1. Sturge-Weber Syndrome: Recommendations for Imaging and Treatment (2016)

   • Consensus recommendations from Sturge-Weber Foundation
   • Imaging protocols, treatment algorithms
   • Evidence-based where available, expert consensus where not

2. International Consensus on Management of Sturge-Weber Syndrome (2018)

   • Multidisciplinary expert consensus
   • Neurological, ophthalmological, and dermatological management
   • Pediatric and adult care pathways

Landmark Studies

Genetics:

• Shirley et al. (2013): First identification of GNAQ mutation in SWS [6]
• Subsequent validation studies confirming somatic mosaicism

Natural History:

• Kossoff et al. (2009): Seizure onset age predicts cognitive outcomes [12]
• Bebin & Gomez (1988): Classification system and prognostic factors

Epilepsy Surgery:

• Arzimanoglou et al. (2000): Hemispherectomy outcomes in SWS [13]
• Gonzalez-Martinez et al. (2005): Early surgery improves neurodevelopmental outcomes

Dermatology:

• Chapas et al. (2007): PDL outcomes for facial PWS - early treatment superior [16]

Ophthalmology:

• Sujansky & Conradi (1995): Glaucoma in SWS - natural history and outcomes [11]

Current Controversies and Evolving Evidence

Aspirin Therapy:

• Ongoing debate about benefit vs risk
• Prospective trials underway
• Practice varies widely between centers [18]

Timing of Hemispherectomy:

• Trend toward earlier surgery (age 2-5) in drug-resistant cases
• Balancing neuroplasticity benefits vs surgical risks in very young children

Targeted Therapies:

• MEK inhibitors (trametinib, selumetinib) targeting GNAQ pathway
• Preclinical and early-phase trials ongoing
• May offer non-surgical treatment option for neurological manifestations [14]

Biomarkers:

• Plasma/CSF biomarkers of disease activity
• Imaging biomarkers (perfusion MRI, MR spectroscopy) to guide treatment
• Genotype-phenotype correlation studies (why do some with mutation have mild disease?)

---

12. Examination Focus (MRCPCH/MRCP/FRCS)

High-Yield Topics for Exams

Written Exams (MCQ/SBA)

Common Question Themes:

1. Genetics:

   • Q: "What is the inheritance pattern of Sturge-Weber Syndrome?"
   • A: Sporadic (somatic mosaicism); NOT inherited; virtually zero recurrence risk

2. Anatomy:

   • Q: "Which trigeminal nerve distribution carries highest risk of brain involvement?"
   • A: Ophthalmic (V1) - forehead and upper eyelid

3. Radiology:

   • Q: "What is the characteristic CT finding in SWS?"
   • A: Gyriform "tram-track" cortical calcification ipsilateral to facial PWS

4. Pathophysiology:

   • Q: "What is the mechanism of cortical injury in SWS?"
   • A: Chronic venous stasis from leptomeningeal angiomatosis → cortical hypoxia → atrophy and calcification

5. Management:

   • Q: "What is the definitive treatment for drug-resistant epilepsy in SWS?"
   • A: Functional hemispherectomy/hemispherotomy (80-90% seizure freedom rate)

6. Ophthalmology:

   • Q: "What is the mechanism of glaucoma in SWS?"
   • A: Elevated episcleral venous pressure from choroidal haemangioma impedes aqueous drainage

Clinical Exams (PACES/OSCE)

Scenario 1: Dermatology/Paediatrics Station

Stem: "Examine this 6-month-old infant's skin and neurological system"

Findings:

• Unilateral facial port-wine stain (V1 distribution)
• Possible mild hemiparesis
• Possible hemianopia (if occipital involvement)

Expected Discussion:

• Diagnosis: Sturge-Weber Syndrome
• Explain triad (skin, brain, eye)
• Investigations: MRI brain with contrast, ophthalmology referral (IOP), EEG
• Management: MDT approach, monitor for seizures, PDL for PWS
• Prognosis: Variable; seizure onset age is key predictor

Examiner Questions:

• "What determines the risk of brain involvement?" (V1 distribution)
• "What complication must be screened for ophthalmologically?" (Glaucoma)
• "What would you see on neuroimaging?" (Leptomeningeal enhancement, atrophy, tram-track calcification)

Scenario 2: Ophthalmology Station

Stem: "This child has an enlarged left eye. What is your differential diagnosis?"

Key Feature: Buphthalmos (congenital glaucoma)

Associated Findings to Seek:

• Facial port-wine stain
• Corneal clouding, Haab's striae
• Epiphora, photophobia

Diagnosis: Congenital glaucoma secondary to Sturge-Weber Syndrome

Management: Urgent ophthalmology referral; likely requires EUA and glaucoma surgery

Viva Voce (Oral Exams)

Viva Question 1: "Explain the genetics of Sturge-Weber Syndrome"

Model Answer: "Sturge-Weber Syndrome is caused by a post-zygotic somatic mutation in the GNAQ gene on chromosome 9q21. The most common mutation is c.548G>A, resulting in p.Arg183Gln. This is an activating mutation in a G-protein signaling pathway component, causing constitutive activation of the Gαq pathway and abnormal vascular development.

The key point is that this mutation occurs after fertilization, during early embryonic development. It affects only a subset of cells derived from the mutated progenitor, explaining the mosaic distribution of features. The mutation is NOT present in germline cells (eggs or sperm), so it is not inherited and recurrence risk in siblings is essentially zero.

Genetic testing requires biopsy of affected tissue (the port-wine stain), not blood, because the mutation may not be present in leukocytes. The mutation is found in approximately 88% of clinically diagnosed SWS cases."

Viva Question 2: "Discuss the role of surgery in SWS"

Model Answer: "Surgery plays two major roles in SWS: epilepsy surgery and glaucoma surgery.

For epilepsy, approximately 30-50% of patients with SWS develop drug-resistant seizures. The surgery of choice is functional hemispherectomy or hemispherotomy, which disconnects the affected hemisphere. This is highly effective, with 80-90% achieving seizure freedom. The ideal candidate has:

• Drug-resistant epilepsy despite adequate trials of AEDs
• Unilateral, well-defined leptomeningeal angiomatosis
• Pre-existing hemiparesis (so they have 'nothing to lose' motorically)

Outcomes are excellent if performed early - neuroplasticity in young children allows remarkable functional compensation by the remaining hemisphere. Expected deficits include hemiplegia (usually pre-existing) and homonymous hemianopia, but seizure freedom often leads to dramatic improvements in cognitive function and quality of life.

For glaucoma, 30-70% of patients require surgical IOP control. Options include goniotomy/trabeculotomy for congenital glaucoma, trabeculectomy, or increasingly, glaucoma drainage devices. Glaucoma in SWS is challenging because the underlying episcleral venous pressure elevation persists despite surgery, so multiple procedures are often needed."

Viva Question 3: "What is the significance of 'tram-track' calcification?"

Model Answer: "Tram-track calcification refers to the characteristic gyriform, parallel linear calcification seen on CT brain in Sturge-Weber Syndrome. It appears as two parallel lines following the cortical gyri, hence 'tram-track.'

Pathophysiologically, this represents dystrophic calcification of the cortex underlying the leptomeningeal angiomatosis. The chronically ischaemic cortex undergoes neuronal death and gliosis, with subsequent calcium deposition primarily in cortical layers II and III.

Key points:

• It's cortical calcification, not vascular calcification
• Usually not visible before 2 years of age; increases with age
• Best seen on CT (superior to MRI for calcification)
• Extent correlates with severity of neurological involvement
• Ipsilateral to the facial port-wine stain and leptomeningeal angiomatosis

On MRI, these calcified areas show blooming artifact on susceptibility-weighted imaging (SWI) or gradient-echo sequences."

---

13. Patient and Family Explanation

What is Sturge-Weber Syndrome?

Sturge-Weber Syndrome is a condition affecting the skin, brain, and eyes. It causes a red birthmark on the face (called a port-wine stain) and can affect the blood vessels in the brain and eye on the same side.

What causes it?

It's caused by a tiny genetic "spelling mistake" that happened while your baby was developing in the womb, very early in pregnancy. This was a random event - nothing you did or didn't do caused it.

Is it inherited? Will my other children have it?

No, it is NOT inherited. The genetic change happened after conception, only in your baby. Your other children are not at increased risk. If your child with SWS has children in the future, they are also not at risk (the genetic change is not in eggs or sperm).

What are the main problems?

1. Birthmark (Port-Wine Stain):

   • The red/purple mark on the face
   • Present from birth, can darken over time
   • Can be treated with laser to make it lighter
   • Does not go away on its own

2. Brain:

   • Abnormal blood vessels in the brain (same side as birthmark)
   • Can cause seizures (epilepsy) - about 75% of children
   • Can cause weakness on one side of body (opposite to birthmark)
   • Can affect learning and development in some children

3. Eyes:

   • High pressure in the eye (glaucoma) - about 30-70% of children
   • Can damage vision if not treated
   • Needs regular eye checks throughout life

What tests does my child need?

• Brain MRI scan: To see if there are abnormal blood vessels in the brain
• Eye exam: To check pressure in the eye (needs to be repeated regularly)
• EEG (brain wave test): To check for seizure activity
• Developmental assessments: To monitor learning and development

What treatments are available?

1. For the birthmark:

   • Laser treatment (Pulsed Dye Laser)
   • Works best if started early (first year of life)
   • Makes the birthmark lighter but rarely removes it completely
   • Needs many treatments over years

2. For seizures:

   • Medication (antiepileptic drugs)
   • Most children's seizures can be controlled with medicine
   • If medicine doesn't work, surgery might be an option
   • Brain surgery can cure seizures in many children with SWS

3. For glaucoma:

   • Eye drops to lower pressure
   • Sometimes needs eye surgery
   • Must be monitored lifelong

4. Support for development:

   • Physiotherapy (if weakness)
   • Occupational therapy
   • Speech therapy (if needed)
   • Educational support at school

What is the outlook for my child?

Every child is different. Some children with SWS have very mild symptoms and do well in school and life. Others have more significant challenges.

Better outlook if:

• Seizures start later (after age 1) or don't happen at all
• Seizures are well-controlled with medication
• Only one side of brain affected
• Eyes are checked and treated regularly

More challenges if:

• Seizures start very early (before age 1)
• Seizures are hard to control
• Both sides of brain affected

The most important things are:

• Starting treatment early
• Good seizure control
• Regular eye checks
• Lots of support for development

Will my child have a normal life span?

Yes, most children with SWS have a normal life span. The main risks are from uncontrolled seizures, which is why controlling seizures is so important.

What support is available?

• Specialist doctors (neurology, ophthalmology, dermatology)
• Specialist nurses
• Therapists (physio, occupational, speech)
• Educational psychologists
• Support groups (Sturge-Weber Foundation, local support groups)
• Parent-to-parent support
• Information resources

What should I watch for?

Seek urgent medical help if:

• First seizure
• Seizures become more frequent or different
• Seizure lasting more than 5 minutes
• Child seems to be losing skills they had before
• Eye becomes red or painful
• Sudden vision problems

Regular monitoring needed:

• Eye checks (every few months when young, then yearly)
• Seizure control
• Developmental progress
• School performance

---

14. References

1. Comi AM. Sturge-Weber syndrome. Handb Clin Neurol. 2015;132:157-168. doi:10.1016/B978-0-444-62702-5.00011-1

2. Higueros E, Roe E, Granell E, Baselga E. Sturge-Weber syndrome: a review. Actas Dermosifiliogr. 2017;108(5):407-417. doi:10.1016/j.ad.2016.09.022

3. Waelchli R, Aylett SE, Robinson K, et al. New vascular classification of port-wine stains: improving prediction of Sturge-Weber risk. Br J Dermatol. 2014;171(4):861-867. doi:10.1111/bjd.13203

4. Sudarsanam A, Ardern-Holmes SL. Sturge-Weber syndrome: from the past to the present. Eur J Paediatr Neurol. 2014;18(3):257-266. doi:10.1016/j.ejpn.2013.10.003

5. Comi AM. Pathophysiology of Sturge-Weber syndrome. J Child Neurol. 2003;18(8):509-516. doi:10.1177/08830738030180080701

6. Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368(21):1971-1979. doi:10.1056/NEJMoa1213507

7. Nakashima M, Miyajima M, Sugano H, et al. The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome. J Hum Genet. 2014;59(12):691-693. doi:10.1038/jhg.2014.95

8. Roach ES. Neurocutaneous syndromes. Pediatr Clin North Am. 1992;39(4):591-620. doi:10.1016/s0031-3955(16)38337-5

9. Griffiths PD, Boodram MB, Blaser S, et al. "Tram-track" calcification in Sturge-Weber syndrome. Pediatr Radiol. 2003;33(5):329-331. doi:10.1007/s00247-003-0882-8

10. Hu J, Yu Y, Juhasz C, et al. MR susceptibility weighted imaging (SWI) complements conventional contrast enhanced T1 weighted MRI in characterizing brain abnormalities of Sturge-Weber Syndrome. J Magn Reson Imaging. 2008;28(2):300-307. doi:10.1002/jmri.21435

11. Sujansky E, Conradi S. Outcome of Sturge-Weber syndrome in 52 adults. Am J Med Genet. 1995;57(1):35-45. doi:10.1002/ajmg.1320570110

12. Kossoff EH, Ferenc L, Comi AM. An infantile-onset, severe, yet sporadic seizure pattern is common in Sturge-Weber syndrome. Epilepsia. 2009;50(9):2154-2157. doi:10.1111/j.1528-1167.2009.02179.x

13. Arzimanoglou AA, Andermann F, Aicardi J, et al. Sturge-Weber syndrome: indications and results of surgery in 20 patients. Neurology. 2000;55(10):1472-1479. doi:10.1212/wnl.55.10.1472

14. Huang L, Couto JA, Pinto A, et al. Somatic GNAQ mutation is enriched in brain endothelial cells in Sturge-Weber syndrome. Pediatr Neurol. 2016;65:59-63. doi:10.1016/j.pediatrneurol.2016.09.016

15. Lin DD, Barker PB, Hatfield LA, Comi AM. Dynamic MR perfusion and proton MR spectroscopic imaging in Sturge-Weber syndrome: correlation with neurological symptoms. J Magn Reson Imaging. 2006;24(2):274-281. doi:10.1002/jmri.20640

16. Chapas AM, Eickhorst K, Geronemus RG. Efficacy of early treatment of facial port-wine stains in newborns: a review of 49 cases. Lasers Surg Med. 2007;39(7):563-568. doi:10.1002/lsm.20519

17. Alkonyi B, Miao Y, Wu J, et al. A sleep-activated electroencephalographic pattern proved to be a strong lateralizing sign in Sturge-Weber syndrome. Epilepsy Res. 2011;95(3):213-220. doi:10.1016/j.eplepsyres.2011.04.004

18. Lance EI, Sreenivasan AK, Zabel TA, Kossoff EH, Comi AM. Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes. J Child Neurol. 2013;28(2):213-218. doi:10.1177/0883073812463068

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists. Always refer to current local guidelines and seek expert advice for complex cases.